tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

CLDX Stock Latest News

Celldex’s Phase 3 Study on Barzolvolimab: A Potential Game-Changer for Chronic Urticaria
Company AnnouncementsCelldex’s Phase 3 Study on Barzolvolimab: A Potential Game-Changer for Chronic Urticaria
9d ago
CLDX
Celldex Therapeutics Advances Phase 3 Trial for Chronic Spontaneous Urticaria Treatment
PremiumCompany Announcements
Celldex Therapeutics Advances Phase 3 Trial for Chronic Spontaneous Urticaria Treatment
11d ago
CLDX
3 Best Stocks to Buy Now, 8/25/2025, According to Top Analysts
PremiumMarket News
3 Best Stocks to Buy Now, 8/25/2025, According to Top Analysts
13d ago
BHVN
CLDX
Celldex’s Barzolvolimab: Promising Safety Profile Supports Buy Rating Despite EoE Trial Setback
PremiumRatings
Celldex’s Barzolvolimab: Promising Safety Profile Supports Buy Rating Despite EoE Trial Setback
16d ago
CLDX
Celldex data supports positive Eupraxia thesis, says H.C. Wainwright
PremiumThe Fly
Celldex data supports positive Eupraxia thesis, says H.C. Wainwright
18d ago
CLDX
EPRX
Celldex price target lowered to $62 from $64 at Canaccord
PremiumThe FlyCelldex price target lowered to $62 from $64 at Canaccord
18d ago
CLDX
Strategic Shift and Promising Developments Justify Buy Rating for Celldex
Premium
Ratings
Strategic Shift and Promising Developments Justify Buy Rating for Celldex
18d ago
CLDX
Celldex price target lowered to $48 from $56 at Citi
Premium
The Fly
Celldex price target lowered to $48 from $56 at Citi
18d ago
CLDX
Celldex price target lowered to $42 from $50 at H.C. Wainwright
PremiumThe Fly
Celldex price target lowered to $42 from $50 at H.C. Wainwright
18d ago
CLDX
Celldex price target lowered to $38 from $44 at Wells Fargo
PremiumThe Fly
Celldex price target lowered to $38 from $44 at Wells Fargo
18d ago
CLDX
Celldex’s Promising Pipeline and Financial Stability Justify Buy Rating Despite Recent Setback
PremiumRatings
Celldex’s Promising Pipeline and Financial Stability Justify Buy Rating Despite Recent Setback
18d ago
CLDX
Closing Bell Movers: La-Z-Boy down 24% after earnings miss
PremiumThe Fly
Closing Bell Movers: La-Z-Boy down 24% after earnings miss
18d ago
ALC
JHX
Celldex down 12.5% at $21.01 after barzolvolimab study update
PremiumThe FlyCelldex down 12.5% at $21.01 after barzolvolimab study update
18d ago
CLDX
Celldex Halts Barzolvolimab Development for EoE
Premium
Company Announcements
Celldex Halts Barzolvolimab Development for EoE
18d ago
8K
CLDX
Celldex says barzolvolimab study meets primary endpoint, will not advance in EoE
Premium
The Fly
Celldex says barzolvolimab study meets primary endpoint, will not advance in EoE
18d ago
CLDX
Celldex’s Barzolvolimab: A Promising EoE Treatment with Significant Market Potential – Buy Rating Justified
PremiumRatings
Celldex’s Barzolvolimab: A Promising EoE Treatment with Significant Market Potential – Buy Rating Justified
20d ago
CLDX
Celldex Therapeutics Reports Increased R&D Expenses Amid Wider Losses
PremiumCompany Announcements
Celldex Therapeutics Reports Increased R&D Expenses Amid Wider Losses
23d ago
CLDX
Celldex’s Phase 3 Study on Barzolvolimab: A Potential Game-Changer for Chronic Spontaneous Urticaria
PremiumCompany Announcements
Celldex’s Phase 3 Study on Barzolvolimab: A Potential Game-Changer for Chronic Spontaneous Urticaria
24d ago
CLDX
Celldex’s Barzolvolimab: A Promising Treatment for Eosinophilic Esophagitis with Market Potential
PremiumRatings
Celldex’s Barzolvolimab: A Promising Treatment for Eosinophilic Esophagitis with Market Potential
25d ago
CLDX
Celldex’s Phase 3 Study on Barzolvolimab: A Potential Game-Changer for Chronic Spontaneous Urticaria
PremiumCompany AnnouncementsCelldex’s Phase 3 Study on Barzolvolimab: A Potential Game-Changer for Chronic Spontaneous Urticaria
26d ago
CLDX
Celldex’s Promising Advancements and Strategic Growth: A Buy Rating from Analyst Sam Slutsky
Premium
Ratings
Celldex’s Promising Advancements and Strategic Growth: A Buy Rating from Analyst Sam Slutsky
30d ago
CLDX
Celldex: Strong Financial Position and Promising Pipeline Drive Buy Rating Despite Risks
Premium
Ratings
Celldex: Strong Financial Position and Promising Pipeline Drive Buy Rating Despite Risks
30d ago
CLDX

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >